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Engineering yeast for high-
level production of stilbenoid 
antioxidants
Mingji Li1, Konstantin Schneider1, Mette Kristensen1, Irina Borodina1 & Jens Nielsen1,2,3
Stilbenoids, including resveratrol and its methylated derivatives, are natural potent antioxidants, 
produced by some plants in trace amounts as defense compounds. Extraction of stilbenoids from 
natural sources is costly due to their low abundance and often limited availability of the plant. Here 
we engineered the yeast Saccharomyces cerevisiae for production of stilbenoids on a simple mineral 
medium typically used for industrial production. We applied a pull-push-block strain engineering 
strategy that included overexpression of the resveratrol biosynthesis pathway, optimization of the 
electron transfer to the cytochrome P450 monooxygenase, increase of the precursors supply, and 
decrease of the pathway intermediates degradation. Fed-batch fermentation of the final strain resulted 
in a final titer of 800 mg l−1 resveratrol, which is by far the highest titer reported to date for production 
of resveratrol from glucose. We further integrated heterologous methyltransferases into the resveratrol 
platform strain and hereby demonstrated for the first time de novo biosynthesis of pinostilbene and 
pterostilbene, which have better stability and uptake in the human body, from glucose.
Resveratrol (3,5,4′ -trihydroxystilbene) is a natural plant defense compound with strong antioxidant activity. The 
therapeutical effects of resveratrol in humans are not documented in terms of mode of action and molecular 
target, but there are several reports on its efficacy for treatment of cardiovascular diseases1–3, cancer4,5 and aging6 
in mice. This makes resveratrol a promising compound for applications as dietary supplement, functional food 
ingredient, cosmetics ingredient, and even as a therapeutic. Several derivatives of resveratrol have been created, 
where the methylated derivatives pinostilbene and pterostilbene showed better stability and uptake7. The market 
for resveratrol and its derivatives is expected to grow further in the future. Currently, resveratrol is predominantly 
extracted from Japanese knotweed Polygonum cuspidatum; however the process is dependent on the variable 
harvest, has low extraction yield and results in a low-purity product8. Production of resveratrol by microbial fer-
mentation presents an alternative process circumventing the mentioned disadvantages of extraction from plants. 
Recombinant production of resveratrol was first shown in S. cerevisiae in 20039. Several groups subsequently 
improved the production of resveratrol and its derivatives in yeast and Escherichia coli. However, all of these 
studies applied feeding of expensive precursors, such as p-coumaric acid10–15, tyrosine15–17 or phenylalanine18. The 
highest reported titer of resveratrol was 2.3 g l−1, when 2.5 g l−1 p-coumaric acid was fed to engineered E. coli19. 
We previously described the biosynthesis of resveratrol directly from glucose and ethanol, via the tyrosine path-
way in yeast, which resulted in production of up to 531 mg l−1 resveratrol in fed-batch fermentation20. Here, we 
describe the development of a S. cerevisiae platform strain for production of resveratrol via phenylalanine path-
way. The platform strain was obtained through extensive metabolic engineering of both the resveratrol pathway 
and pathways forming precursors for its biosynthesis, and it demonstrates clearly that for efficient production of 
plant chemicals by microbial fermentation it is necessary to combine pathway reconstruction with engineering of 
the endogenous metabolism21. We evaluated the platform strain for high-level production of resveratrol and also 
demonstrated its use for production of resveratrol derivatives.
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Results
Reconstruction of resveratrol biosynthetic pathway in S. cerevisiae. The resveratrol biosynthesis 
pathway (Fig. 1a) was reconstructed in yeast by introducing phenylalanine ammonia lyase (AtPAL2), cinnamic 
acid hydroxylase (AtC4H), p-coumaryl-CoA ligase (At4CL2) from Arabidopsis thaliana and resveratrol synthase 
(VvVST1) from Vitis vinifera. Two strong constitute promoters, pTEF1 and pPGK1, were employed to control 
gene expression in different combinations. Engineered cells were cultivated on mineral medium supplemented 
with 5 mM phenylalanine for 72 hours to obtain 20–33 mg l−1 of resveratrol (Fig. 1b). No by-products (cinnamic 
acid or p-coumaric acid) were detected in the medium. The highest titer of 32.32 ± 0.37 mg l−1 was obtained for 
the strain ST4978, which had AtPAL2 and VvVST1 genes under control of pTEF1 promoter, and the other two 
genes under control of the pPGK1 promoter. Considering that the pTEF1 promoter is somewhat stronger than 
pPGK122, the results imply that AtPAL2 and VvVST1 may be rate limiting. This would also explain the absence of 
accumulation of pathway intermediates.
Enhancement of P450 activity. Many cytochrome P450 monooxygenases present a challenge, when 
expressed in a heterologous host, due to their notorious low activity, limited stability, NAD(P)H-dependence, 
and auxiliary of electron carrier proteins23. As C4H used in resveratrol pathway is a membrane-associated 
plant-derived P450 enzyme, which requires an electron carrier for optimal activity, we hypothesized that C4H 
activity may be limiting resveratrol production. Plant-derived P450s have previously been reported to poorly 
accept electrons directly from yeast endogenous electron carriers24. Thus, we upgraded the strain ST4978 
(basic resveratrol pathway) with overexpression of cytochrome P450 reductase (AtATR2) from A. thaliana or 
cytochrome B5 (CYB5) from S. cerevisiae or both (Fig. 2). Overexpression of CYB5 did not improve resveratrol 
production on mineral medium with 5 mM phenylalanine supplementation (Fig. 2b, ST4980), possibly due to 
inability to directly donate electrons to C4H and due to induction of membrane proliferation25. On the other 
hand, resveratrol titer increased from 32.32 ± 0.37 to 40.75 ± 1.60 mg l−1 when AtATR2 was introduced (Fig. 2b, 
ST4981), and further increased to 77.19 ± 0.84 mg l−1 when CYB5 was subsequently overexpressed (Fig. 2b, 
ST4982), which corresponds to 26% and 139% improvement in relation to the reference strain ST4978. Trace 
amount of p-coumaric acid was also detected during the cultivation process (at 24 h) of the strain ST4982, but not 
in the other strains. Thus, the activity of C4H was clearly enhanced when ATR2 and Cyb5p were overexpressed.
We then tested resveratrol production from glucose by the engineered strains on mineral medium without 
supplementation of phenylalanine. Interestingly, higher resveratrol production was obtained for all the strains 
without phenylalanine supplementation (Fig. 2c). This shows that resveratrol can be de novo synthesized from 
glucose via the phenylalanine pathway and that adding phenylalanine to the medium inhibits resveratrol produc-
tion. The inhibition effect of phenylalanine was more obvious when AtATR2 was expressed (Fig. 2b,c). ST4981 
and ST4982 resulted in 78.30 ± 1.93 mg l−1 and 105.31 ± 12.59 mg l−1 resveratrol respectively on mineral medium 
without phenylalanine, which was 92% and 36% higher than resveratrol production with phenylalanine supple-
mentation. We also observed that, with the increase of phenylalanine concentration from 0 to 5 mM, the biomass 
accumulation increased (Supplementary Fig. 1).
Increasing copy number of the resveratrol pathway genes. We have previously shown that for 
tyrosine-mediated resveratrol biosynthesis the production of resveratrol could be increased 36-fold by integra-
tion of multiple copies of the biosynthetic genes20. We therefore tested whether the same pull-strategy would 
work for the phenylalanine-mediated pathway. The basic resveratrol biosynthesis pathway genes (AtPAL2, AtC4H, 
At4CL2 and VvVST1) were integrated onto Ty-elements in the AtATR2 and CYB5 overexpression strain. The 
weakened URA3 marker ensures multiple integrations of the expression cassette26. 12 isolates were screened 
Figure 1. (a) The resveratrol biosynthetic pathway. AtPAL2, phenylalanine ammonia lyase from A. thaliana; 
AtC4H, cinnamic acid hydroxylase from A. thaliana; At4CL2, p-coumaryl-CoA ligase from A. thaliana; 
VvVST1, resveratrol synthase from V. vinifera. (b) Resveratrol production by engineered strains expressing the 
four biosynthetic genes from different promoters. The resveratrol concentration in the broth was measured after 
the cells were cultivated on mineral medium with 2% glucose and 5 mM phenylalanine for 72 hours in 96-deep-
well plates. The displayed average values and standard deviations were calculated from biological triplicates.
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to identify the highest producing strain ST4984, which had 2 copies of the resveratrol pathway genes when 
checked by qPCR. When the strain ST4984 was cultivated on mineral medium with 2% glucose in shake flasks, 
169.04 ± 2.42 mg l−1 resveratrol was obtained (Fig. 3a). In contrast, only 108.31 ± 4.68 mg l−1 resveratrol was 
obtained with strain ST4982 carrying a single copy of the resveratrol pathway. Resveratrol production was growth 
associated (Fig. 3b,c). About 17% and 26% of the total resveratrol were produced during the growth on glucose 
for ST4982 and ST4984 respectively, while the majority of resveratrol was produced during growth on ethanol for 
both strains (Fig. 3a). One possible explanation for the higher production of resveratrol in the ethanol consump-
tion phase can be increased availability of cytosolic acetyl-CoA, which is an intermediate in ethanol assimilation. 
This is consistent with the results we have obtained in our previous study20. The effect of the multicopy gene inte-
gration was however mostly pronounced in the glucose phase, where 2.4-fold more resveratrol was produced in 
ST4984 than in ST4982. For the ethanol phase the relative increase was smaller, namely 1.4-fold. Interestingly the 
multicopy strain ST4984 had a lower biomass yield on ethanol than ST4982, while the biomass yields on glucose 
were similar (Fig. 3b). The final OD600 of ST4984 was 30% lower than that of ST4982 (Fig. 3c) probably due to the 
metabolic burden brought by the high-level expression of the resveratrol pathway enzymes.
Precursor supply. To further improve resveratrol production we applied a push-and-block strategy, where 
we overexpressed the upstream pathways and eliminated competing pathways for the precursor phenylalanine. 
To increase precursors supply, the feedback-inhibition resistant versions of DAHP synthase (ARO4K229L) and 
chorismate mutase (ARO7G141S)27 and a de-regulated variant of acetyl-CoA carboxylase (ACC1S659A, S1157A)28 were 
overexpressed in ST4984 to generate ST4985. The strain ST4985 resulted in a 19% improvement of resveratrol 
production to 201.72 ± 7.91 mg l−1 (Fig. 4b), which is supported by our previous study20. The strain ST4985 was 
further modified by the following strategies and combinations thereof in order to increase the push by overpro-
duction of precursors: (i) deletion of phenylpyruvate decarboxylase (ARO10), (ii) overexpression of a heterol-
ogous shikimate kinase (aroL) from E. coli, (iii) overexpression of a post-translationally non-regulated version 
of acetyl-CoA synthase (SeACSL641P) from Salmonella enterica29. While each of the tested strategies individually 
Figure 2. (a) Cytochrome P450 reductase (CPR)-mediated electron transfer from NADPH to cinnamic acid 
hydroxylase (AtC4H) and effects of functional expression of CPR (AtATR2) and cytochrome B5 (CYB5) on 
resveratrol production on mineral medium with (b) and without (c) 5 mM phenylalanine in 96-deep-well plates. 
The displayed average values and standard deviations were calculated from three biological replicates.
Figure 3. (a) Resveratrol production from glucose by strains carrying single and multiple copies of resveratrol 
pathway. Resveratrol titer in relation to substrate consumption in glucose phase (b) and ethanol phase (c) by 
the engineered strains. The strains were cultivated on mineral medium with 20 g l−1 glucose in shake flasks. The 
displayed average values and standard deviations were calculated from three biological replicates.
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resulted in 26–30% increase of resveratrol titer, their effects was not additive upon combination (Fig. 4b). No 
by-products, such as p-coumaric acid or cinnamic acid, were observed at the end of cultivation process in any of 
the strains. The highest production of resveratrol (272.64 ± 1.34 mg l−1) was obtained in strain ST4990, in which 
ARO10 was deleted and SeACSL641P was overexpressed.
Fed-batch fermentation. Fed-batch fermentation of the engineered strain ST4990 was performed in con-
trolled bioreactors on mineral medium with glucose (Fig. 5a) or ethanol (Fig. 5b) feed in the feeding phase. The 
batch phase was on 40 g l−1 glucose, once the glucose was consumed, the constant feeding of glucose or ethanol 
was initiated. A long lag phase of 40 h was observed followed by a fast growing log phase with the rapid consump-
tion of glucose (Fig. 5). Resveratrol accumulation was growth-associated and reached 268.70 mg l−1 with a yield of 
11.35 mg g−1 glucose when glucose was depleted. A nearly linear increase in OD600 over time was observed while 
glucose or ethanol was being fed. The OD600 increase and resveratrol accumulation corresponded well with the 
substrate consumption (Fig. 5a,b). At the end of the glucose fed-batch fermentation, 812 mg l−1 resveratrol and 
22 g l−1 dry weight (DW) biomass was obtained from feeding 88 g l−1 glucose. In the ethanol fed-batch fermenta-
tion, where 79 g l−1 ethanol was fed, the final concentrations of DW biomass (19 g l−1) and resveratrol (755 mg l−1) 
were similar to the reactors with glucose feeding strategy.
Production of resveratrol derivatives. The instability of resveratrol, which is sensitive to light and 
oxygen, limits the bioavailability and bioactivity of the compound30. The bioactivity and bioavailability of 
resveratrol can be enhanced by substitution of hydroxyl groups with methoxy groups31,32. Two resveratrol 
O-methyltransferases from Sorghum bicolor (SbROMT) and Vitis vinifera (VvROMT) were shown to methylate 
resveratrol to pinostilbene and pterostilbene, respectively (Fig. 6a)11,13. We expressed the two enzymes in the 
resveratrol producing strain ST4990 to generate strains ST4993 and ST4994. Growing the strains ST4993 and 
ST4994 on mineral medium with 20 g l−1 glucose resulted in 1.38 ± 0.06 mg l−1 pinostilbene and 5.52 ± 2.84 mg l−1 
pterostilbene, respectively (Fig. 6b). When grown on feed-in-time (FIT) medium, the strain ST4993 accumu-
lated 5.52 ± 2.84 mg l−1 pinostilbene and strain ST4994 accumulated 34.93 ± 8.53 mg l−1 pterostilbene (Fig. 6c). 
Interestingly, 1.96 ± 0.42 mg l−1 pinostilbene was also observed in ST4994 culture (Fig. 6c), which indicates that 
the two methylation groups are introduced sequentially, as also proposed before by Wang et al.13. Although only 
small amounts of resveratrol derivatives were detected, it demonstrates for the first time the feasibility of de novo 
biosynthesis of the two resveratrol derivatives from glucose.
Figure 4. (a) Schematic overview of resveratrol biosynthesis in engineered yeast S. cerevisiae and the main 
engineering targets implemented in this study. Single arrows represent single reaction steps, while two arrows 
represent multiple reaction steps. The modified targets are shown in red, while the gene ARO10 subjected to 
deletion is shown in blue. Arrows shown in bold indicate that the genes were overexpressed. GLC, glucose; G6P, 
glucose 6-phosphate; E4P, erythrose 4-phosphate; DAHP, 3-deoxy-D-arabino-heptulosonic acid 7-phosphate, 
SHIK, shikimate; S3P, shikimate 3-phosphate; CHOR, chorismate; PREPH, prephenate; TYR, tyrosine; PPY, 
phenylpyruvate; PAA, phenylacetaldehyde; PHE, phenylalanine; CA, cinnamic acid; p-CA, p-coumaric acid; 
p-C-CoA, p-coumaroyl-CoA; RES, resveratrol; M-CoA, malonyl-CoA; Ac-CoA, acetyl-CoA; ACE, acetate; 
ACD, acetaldehyde; ETOH, ethanol; PYR, pyruvate; PEP, phosphoenolpyruvate; ARO4K229L, feedback-inhibition 
resistant version of DAHP synthase; ARO7G141S, feedback-inhibition resistant version of chorismate mutase; 
EcaroL, E. coli shikimate kinase II; ARO10, phenylpyruvate decarboxylase, AtPAL2, phenylalanine ammonia 
lyase; AtC4H, cinnamate-4-hydroxylase; At4CL2, 4-coumarate-CoA ligase; VvVST1, resveratrol synthase; 
SeACSL641P, post-translationally de-regulated variant of acetyl-CoA synthetase; ACC1S659A, S1157A, acetyl-CoA 
carboxylase devoid of SNF1-phosphorylation sites. (b) Microbial production of resveratrol from glucose by 
strains with different genetic modifications. The strains were cultivated on mineral medium with 20 g l−1 glucose 
in shake flasks. The displayed average values and standard deviations were calculated from three biological 
replicates.
www.nature.com/scientificreports/
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Discussion
We have applied a pull-push-block strategy to improve resveratrol production. The “pull” was improved by opti-
mizing the resveratrol pathway expression and P450 function, the “push” was achieved by increasing the supply 
of precursors phenylalanine and malonyl-CoA, and finally the “block” was realized by reducing the degradation 
of the pathway intermediates.
In earlier reports on resveratrol production via phenylalanine, the cultures were supplemented with phenyla-
lanine. For example, Trantas et al. have reported a yeast strain that produced 0.29 mg l−1 resveratrol when 10 mM 
phenylalanine was fed to the medium18. We found that supplementation of the medium with as little as 0.25 mM 
phenylalanine decreased resveratrol titer. This phenomena could be explained by the inhibitory effect of pheny-
lalanine on C4H33. We previously succeeded in inserting up to 8 copies of the resveratrol pathway (TAL) onto 
yeast genome20. However, here where we produce resveratrol via phenylalanine we managed to integrate only 2 
copies of the genes encoding the resveratrol pathway enzymes. The failure to obtain integration of more copies 
of the genes may result from heavy stress response, such as ER membrane proliferation34 or ER morphology 
variation35, when the P450 enzyme is highly expressed. Another plausible explanation might be that the yeast 
host would incur too much metabolic burden if the copy number of resveratrol pathway integrated onto the 
genome were very high and this causes a major shift in protein allocation, which has recently been shown to have 
significant impact on yeast metabolism36. The decreased yield of biomass on glucose that was observed in the 
multicopy strain is consistent with this hypothesis. In addition, we also observed that accumulation of resveratrol 
was strongly related to growth, which is also supported by recently published study on requirement of ATP for 
resveratrol production37.
Overexpression of feedback-inhibition resistant versions of DAHP synthase (ARO4K229L) and chorismate 
mutase (ARO7G141S) together with constitutively active acetyl-CoA carboxylase (ACC1S659A, S1157A) gave a 19% 
improvement in resveratrol titer, which is similar to the increase we observed in the previous study for TAL 
pathway20. We further improved phenylalanine supply by inactivating phenylpyruvate decarboxylase. Two 
broad-substrate-specificity decarboxylases, Aro10p and Pdc5p, were reported to catalyze decarboxylation of phe-
nylpyruvate to phenylacetaldehyde, i.e., the first degradation step38. Although a previous study showed that dou-
ble deletion of ARO10 and PDC5 improved p-coumaric acid production39, no further improvement of resveratrol 
Figure 5. Fed-batch fermentation of the strain ST4990. Aerobic fed-batch fermentations were carried out by 
feeding glucose (a) or ethanol (b) respectively with a constant feeding rate of 5 g h−1 or 10 g h−1.
Figure 6. (a) Methylation of resveratrol to produce its derivatives, pinostilbene and pterostilbene, by strains 
ST4993 and ST4994 carrying SbROMT and VvROMT respectively. The strains were cultivated on mineral 
medium with 20 g l−1 glucose (b) or on FIT medium (c) in shake flasks. The displayed average values and 
standard deviations were calculated from duplicates.
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production was obtained when PDC5 was knocked out in addition to ARO10 (Supplementary Fig. 2). This is 
consistent with publication by Vuralhan et al., who found that Aro10p had higher activity than Pdc5p towards 
phenylpyruvate40. In addition, the supply of malonyl-CoA, another key precursor for resveratrol, would be atten-
uated when PDC5 was knocked out as Pdc5p is also responsible for pyruvate decarboxylation. We have previously 
obtained negative results upon combined overexpression of ScACSL641P and ALD620. On the other hand, overex-
pression of ALD6 may lead to reduction of phenylalanine supply through the Ehrlich pathway38. Consequently, 
in this study we chose to overexpress SeACSL641P alone, which resulted in improvement of resveratrol production. 
Further strategies for increasing malonyl-CoA supply could be envisioned, such as down-regulation of the com-
peting pathway towards fatty acid biosynthesis19.
While the final strain harbored a dozen of genetic modifications, the resveratrol yield (0.007 mol mol−1 glu-
cose) was still far lower than the maximum theoretical yield of 0.28 mol mol−1 glucose37, which shows that there 
is a lot of potential to further improve the strain. One of the strategies that would be interesting to test could 
be optimization of the energetics of cytosolic acetyl-CoA generation by overexpression of bacterial pyruvate 
dehydrogenase complex in the cytosol as recently reported by Kozak et al.41. Besides, strong correlation between 
resveratrol biosynthesis and biomass indicates that low biomass is another issue to be solved for improving 
resveratrol production. Therefore, decoupling growth and production as illustrated recently using a biosensor for 
malonyl-CoA42 could possibly further increase the production of resveratrol.
Methods and Materials
Strains and plasmids. All the engineered yeast strains (Table 1) were constructed from CEN.PK102-5B 
(MATa ura3-52 his3Δ 1 leu2-3/112 MAL2-8c SUC2)43. Genetic engineering was carried out using either integrative 
EasyClone vectors with auxotrophic selection markers44 or using EasyClone-MarkerFree vectors with CRISPR/
Cas9 system45. Details on the cloning and strain construction are provided in Supplementary Information. All the 
oligos used for genetic modifications are listed in Supplementary Table 1. All the biobricks and plasmids used in 
the study are summarized in Supplementary Tables 2 and 3 respectively.
Media and cultivations. Seed cultures were prepared by cultivating yeast in SC Drop-out (SD) liquid 
medium without histidine, leucine and uracil at 30 °C with 250 rpm agitation for 24 h. The inoculation size of 10% 
(v/v) for 96-deep well plate cultivation or initial OD600 of 0.02 for shake flask cultivation was used. The mineral 
medium (pH 6.0) with 2% glucose or feed-in-time (FIT) medium (m2p-labs, Inc.) and cultivation conditions 
for resveratrol and its derivatives production was described in ref. 20. Samples were taken at regular intervals 
Strains Genotype Reference
ST4976 PPGK1-> AtPAL2, PTEF1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1 This study
ST4977 PPGK1-> AtPAL2, PTEF1-> AtC4H, PTEF1-> At4CL2, PPGK1-> VvVST1 This study
ST4978 PTEF1-> AtPAL2, PPGK1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1 This study
ST4979 PTEF1-> AtPAL2, PPGK1-> AtC4H, PTEF1-> At4CL2, PPGK1-> VvVST1 This study
ST4980 PTEF1-> AtPAL2, PPGK1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1, PTEF1-> CYB5 This study
ST4981 PTEF1-> AtPAL2, PPGK1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1, PTEF1-> AtATR2 This study
ST4982 PTEF1-> AtPAL2, PPGK1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1, PTEF1-> AtATR2, PPGK1-> CYB5 This study
ST4984 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1) This study
ST4985 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L
This study
ST691 MATa ura3-52 his3∆1 leu2-3/112 MAL2-8c SUC2, ΔARO10, ΔPDC5 39
ST4986 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10
This study
ST4995 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10, ΔPDC5
This study
ST4987 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, PTEF1-> EcaroL
This study
ST4988 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, PTDH3-> SeACSL641P
This study
ST4989 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10, PTEF1-> EcaroL
This study
ST4990 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10, PTDH3-> SeACSL641P
This study
ST4991 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, PTEF1-> EcaroL, PTDH3-> SeACSL641P
This study
ST4992 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10, PTEF1-> EcaroL, PTDH3-> SeACSL641P
This study
ST4993 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10, PTDH3-> SeACSL641P, PTDH3-> SbROMT
This study
ST4994 PTEF1-> AtATR2, PPGK1-> CYB5, Ty-(PTDH3-> AtPAL2, PFBA1-> AtC4H, PPGK1-> At4CL2, PTEF1-> VvVST1), PTEF1-> ACC1
S659A, S1157A, 
PTEF1-> ARO7G141S, PPGK1-> ARO4 K229 L, ΔARO10, PTDH3-> SeACSL641P, PTDH3-> VvROMT
This study
Table 1.  List of yeast strains used in the study.
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or at the end of cultivation. OD was measured at a wavelength of 600 nm using a Genesys 20 spectrophotometer 
(Thermo Scientific). The dry cell weight was measured by filtrating 3 ml of the cultures through membrane filters 
and drying at 105 °C to a constant weight. Part of the sample was centrifuged at 12,000 rpm for 2 min and the 
supernatant was used for analysis of general secreted metabolites. Another part of the sample was mixed with an 
equal volume of ethanol (99.9%), centrifuged at 12,000 rpm for 2 min and the supernatant was used for resveratrol 
quantification.
HPLC and LC-MS measurements. Glucose and ethanol concentrations were quantified by HPLC 
(Thermo Fisher Scientific, CA) equipped with an Aminex HPX-87H ion-exchange column (Bio-Rad, Hercules, 
CA) and a UV and RI detector. 5 mM H2SO4 was used as the mobile phase and the column was kept at 45 °C with 
a flow rate of 0.6 ml min−1. The HPLC detection was carried out with 10 mM ammonium formate (pH 3.0) and 
acetonitrile as the eluents at a linear gradient flow rate of acetonitrile from 5% to 60% with a Discovery HS F5 
150 mm × 2.1 mm column (particle size 3 mm) as described in ref. 20. The analyses of pinostilbene and pteros-
tilbene were performed by LC-MS (Thermo Fisher Scientific, CA). Confirmation of the identity of pinostilbene 
and pterostilbene was done by comparing the retention time and accurate mass spectrum with the standards 
purchased from Sigma-Aldrich. The details on LC-MS analysis are provided in Supplementary Information.
Fed-batch fermentation. Fermentation was carried out in Sartorius bioreactors equipped with an acoustic 
gas analyzer (model number 1311, Bruël & Kjær). An initial OD600 of 0.2 was used for inoculation of seed culture 
into 0.4 l mineral medium containing 4% glucose. During the fermentation the temperature was maintained at 
30 °C, pH at 6.0 with NH4·H2O, agitation rate at 800 rpm, and air flow at 1 l min−1. The detailed setup for batch 
and fed-batch fermentation is described in Supplementary Information.
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